Skip to main content

Table 1 Demographics and baseline characteristics

From: A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

Latanoprost concentration (μg/mL)
  50 75 100 125
ITT Population, N 71 70 72 69
Sex, n (%)
 Male 32 (45.1) 35 (50.0) 42 (58.3) 35 (50.7)
 Female 39 (54.9) 35 (50.0) 30 (41.7) 34 (49.3)
Race, n (%)
 Caucasian 56 (78.9) 57 (81.4) 55 (76.4) 56 (81.2)
 Black 1 (1.4) 0 (0) 2 (2.8) 1 (1.4)
 Asian 14 (19.7) 13 (18.6) 15 (20.8) 12 (17.4)
Age (years)
 Mean ± SD 59.5 ± 12.8 59.5 ± 12.0 60.6 ± 13.8 61.2 ± 12.7
 Median 61.0 59.0 60.5 63.0
 Range 20-82 26-85 20-85 26-89
Study eye, n (%)
 Right 16 (22.5) 15 (21.4) 13 (18.1) 11 (15.9)
 Left 8 (11.3) 8 (11.4) 11 (15.3) 16 (23.2)
 Both 47 (66.2) 47 (67.1) 48 (66.7) 42 (60.9)
Treated eye, n (%)
 Right 7 (9.9) 5 (7.1) 3 (4.2) 4 (5.8)
 Left 1 (1.4) 1 (1.4) 2 (2.8) 4 (5.8)
 Both 63 (88.7) 64 (91.4) 67 (93.1) 61 (88.4)
Worse eye, n (%)
 Right 50 (70.4) 43 (61.4) 39 (54.2) 36 (52.2)
 Left 21 (29.6) 27 (38.6) 33 (45.8) 33 (47.8)
Eye color, n (%)
 Homogenous blue, gray or green 8 (11.3) 11 (15.7) 4 (5.6) 11 (15.9)
 Homogenous brown 45 (63.4) 43 (61.4) 46 (63.9) 40 (58.0)
 Blue-brown or gray-brown 10 (14.1) 12 (17.1) 11 (15.3) 11 (15.9)
 Green-brown 4 (5.6) 3 (4.3) 8 (11.1) 4 (5.8)
 Yellow-brown 3 (4.2) 1(1.4) 3 (4.2) 3 (4.3)
 Different* 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0)
Diagnosis , n (%)
 Primary open-angle glaucoma 53 (74.6) 44 (62.9) 47 (65.3) 47 (68.1)
 Ocular hypertension 16 (22.5) 18 (25.7) 21 (29.2) 16 (23.2)
 Different* 2 (2.8) 8 (11.4) 4 (5.6) 6 (8.7)
IOP-lowering medication at
screening, n%
 Alpha agonists 3 (4.2) 5 (7.1) 6 (8.3) 1 (1.4)
 Beta-blockers 33 (46.5) 28 (40.0) 26 (36.1) 23 (33.3)
 Carbonic anhydrase inhibitors 7 (9.9) 8 (11.4) 2 (2.8) 2 (2.9)
 Combination drugs 9 (12.7) 6 (8.6) 4 (5.6) 5 (7.2)
 Parasympathomimetics 0 (0.0) 1 (1.4) 0 (0.0) 2 (2.9)
 Prostaglandins 23 (32.4) 19 (27.1) 20 (27.8) 20 (29.0)
 Sympathomimetics 1 (1.4) 1 (1.4) 0 (0.0) 0 (0.0)
PP Population, N 69 66 71 68
Baseline IOP
Worse eye8 a.m.
 Mean ± SD 26.9 ± 3.1 26.6 ± 3.0 26.5 ± 2.5 26.8 ± 2.8
 Range 24.0 – 36.0 24.0 – 36.0 24.0 – 35.0 24.0 – 36.0
4 p.m.
 Mean ± SD 25.3 ± 3.6 24.6 ± 3.5 25.3 ± 3.1 25.7 ± 3.7
 Range 16.5 – 37.0 15.0 –35.0 17.5 – 34.0 18.0 – 36.0
Study eye
8 a.m.
 Mean ± SD 26.5 ± 2.8 26.1 ± 2.5 26.2 ± 2.4 26.4 ± 2.4
 Range 24.0 – 34.0 24.0 – 36.0 24.0 – 35.0 24.0 – 34.0
4 p.m.
 Mean ± SD 25.1 ± 3.4 24.3 ± 3.1 25.1 ± 2.9 25.3 ± 3.3
 Range 16.5 – 35.0 15.5 – 34.0 18.0 – 34.0 18.0 – 36.0
  1. IOP intraocular pressure, ITT intention-to-treat, PP per protocol, SD standard deviation.
  2. *If the diagnosis/eye color of a subjects eye was not the same in both eyes, the outcome was given as different.
  3. By subject (i.e. diagnoses for both eyes of the subject were combined).